Medical Condition News

RSS

Orexo partner submits NDA for cancer pain drug Abstral in Japan

Orexo AB today announces that its partner Kyowa Hakko Kirin Co., Ltd. has submitted the New Drug Application (NDA) in Japan for the cancer pain drug KW-2246 (Abstral).

25 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Identification of gaps in accessing stroke centers cuts down the deadly toll of stroke

When stroke strikes, choking off blood supply to the brain, every minute counts: Nearly 2 million neurons die each minute a stroke is left untreated, making it a race to recognize symptoms so that lifesaving "clot-busting" drugs can be administered.

25 Feb 2010

Rapamycin may hold promise for Alzheimer's disease

Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia.

25 Feb 2010

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD).

25 Feb 2010

Inverseon comments on LABAs and INV102CR drugs

Inverseon, Inc. (http://www.inverseon.com) comments on Long Acting Beta-Agonists (LABAs) and INV102CR.

25 Feb 2010

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

25 Feb 2010

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

The new Jefferson Vascular Center at Thomas Jefferson University Hospital offers an integrated, multidisciplinary approach to the diagnosis, management and treatment of vascular diseases (diseases of blood vessels) and thrombotic (blood-clotting) disorders all under one roof.

25 Feb 2010

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

Researchers from the Toronto Western Research Institute noted a higher prevalence of arthritis and arthritis-attributable activity limitations (AAL) in the U.S. versus the Canadian population. The authors attribute the higher prevalence of arthritis and AAL to a greater level of obesity and physical inactivity in Americans, particularly women.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

End-stage ankle arthritis: New treatment options for baby boomers

There's good news for active older adults who are plagued with arthritic ankles. Surgeons presenting today at the American College of Foot and Ankle Surgeons' Annual Scientific Conference in Las Vegas are re-thinking treatment approaches for end-stage ankle arthritis.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Nearly four in 10 transient ischemic attack (TIA) and minor ischemic stroke patients may experience mental impairment, according to a study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Single or unhappily married men may have an elevated risk of fatal stroke in the coming decades, according to a large study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Genetic Disorder Tracker introduced by Guidepoint Global

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.

25 Feb 2010

More young people are having strokes while older people are having fewer: Study

More young people are having strokes while older people are having fewer, according to data from Ohio and Kentucky presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Medical Condition News

Orexo partner submits NDA for cancer pain drug Abstral in Japan

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Identification of gaps in accessing stroke centers cuts down the deadly toll of stroke

Rapamycin may hold promise for Alzheimer's disease

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

Inverseon comments on LABAs and INV102CR drugs

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

EpiCept provides business update and fourth-quarter financial highlights

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

End-stage ankle arthritis: New treatment options for baby boomers

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Genetic Disorder Tracker introduced by Guidepoint Global

More young people are having strokes while older people are having fewer: Study

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News